Home > Insider Trading > Filing (0001209191-18-061860)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1388658	Irhythm Technologies Inc.	IRTC	Surgical & Medical Instruments & Apparatus (3841)	208149544

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1670676	A David Vort	C/O Irhythm Technologies, Inc. 650 Townsend Street, Suite 500 San Francisco CA 94103	Evp, Sales	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-12-07	4,500	$3.65	26,320	No	4	M	Direct
Common Stock	Disposition	2018-12-07	5,176	$73.31	21,144	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2018-12-07	4,500	$0.00	4,500	$3.65

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
90,794		2024-02-04	No	4	M	Direct

Footnotes

Includes 323 shares acquired pursuant to the issuer's 2016 Employee Stock Purchase Plan (the "Plan") on June 1, 2018 and 353 shares acquired pursuant to the Plan on December 1, 2018. Reflects a corrective decrease of 1,077 shares resulting from the duplicate reporting in Forms 4 filed September 13, 2017 and March 1, 2018 of 1,077 shares acquired pursuant to the Plan on June 1, 2017.
This transaction was executed in multiple trades at prices ranging from $73.2836 to $73.4458. The prices reported above reflects the weightedaverage sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of theissuer full information regarding the number of shares and prices at which the transaction was effected.
The option vested and the shares became exercisable according to the following schedule: 1/4 on January 1, 2015 and 1/36 of the remaining shares on each full calendar month thereafter.